Misplaced Pages

Oligohydramnios
Specialty	Obstetrics

Oligohydramnios is a medical condition in pregnancy characterized by a deficiency of amniotic fluid, the fluid that surrounds the fetus in the abdomen, in the amniotic sac. The limiting case is anhydramnios, where there is a complete absence of amniotic fluid. It is typically diagnosed by ultrasound when the amniotic fluid index (AFI) measures less than 5 cm or when the single deepest pocket (SDP) of amniotic fluid measures less than 2 cm. Amniotic fluid is necessary to allow for normal fetal movement, lung development, and cushioning from uterine compression. Low amniotic fluid can be attributed to a maternal, fetal, placental or idiopathic cause and can result in poor fetal outcomes including death. The prognosis of the fetus is dependent on the etiology, gestational age at diagnosis, and the severity of the oligohydramnios.

The opposite of oligohydramnios is polyhydramnios, or an excess of amniotic fluid.

Background

Amniotic fluid is a clear, watery substance that surrounds the fetus. It helps to maintain a constant temperature around the fetus, cushion it from injury, and allows for proper fetal movement and organ development. The cause of anhydramnios is not always clear, but several factors can contribute to its development such as fetal renal abnormalities or placental insufficiency. Untreated anhydramnios can lead to serious complications for the baby, including pulmonary hypoplasia or skeletal deformities.

Etiology

The amount of amniotic fluid available is based on how much fluid is produced and how much is removed from the amniotic sac. In the first trimester, the main sources of amniotic fluid are fetal lung secretions, transportation of maternal plasma across the fetal membranes, and the surface of the placenta. By the second trimester, the fetal kidneys start to produce urine which becomes the main source of the amniotic fluid for the remainder of the pregnancy.

The development of oligohydramnios may be idiopathic or have a maternal, fetal, or placental cause.

Maternal

• Conditions such as preeclampsia, chronic hypertension, collagen vascular disease, nephropathy, and thrombophilia cause uteroplacental insufficiency. These conditions decrease the blood flow to vital organs such as the placenta which supplies blood, oxygen, and nutrients to the developing fetus. Decreased blood flow to the fetus causes impaired urine production which leads to reduced amniotic fluid and oligohydramnios.
• Medications such as angiotensin converting enzyme inhibitors (lisinopril), prostaglandin synthetase inhibitors (NSAIDs, anti-inflammatory steroids), and trastuzumab decrease blood flow to the kidneys of the fetus. When the fetal kidneys are not able to produce adequate amounts of urine, this leads to reduced amniotic fluid or oligohydramnios. Some medications, such as nimesulide and chemotherapeutic agents, have been linked to anhydramnios.
• Maternal dehydration, including severe diarrhea, vomiting, or excessive fluid loss.
• Infections such as the TORCH infections (Toxoplasma gondii, rubella, cytomegalovirus, herpes simplex virus) and parvovirus B19

Fetal

• Chromosomal abnormalities such as Down syndrome which are associated with gastrointestinal abnormalities
• Congenital abnormalities such as renal agenesis and cystic renal disease are associated with impaired urine production, and posterior urethral valves or urethral atresia which are associated with obstruction of the lower urinary tract. Fetal renal abnormalities can encompass various kidney-related issues, including bilateral renal agenesis, also known as Potter syndrome, which is the most prevalent cause of anhydramnios.
• Intrauterine demise
• Post-term pregnancy
• Rupture of membranes
• Intrauterine growth restriction (IUGR) associated with placental insufficiency. Insufficient fetal growth can result in reduced amniotic fluid volume. When the fetus is not growing appropriately, it may have a reduced ability to produce urine, which is a significant contributor to amniotic fluid.
• Amnion nodosum; failure of secretion by the cells of the amnion covering the placenta

Placental

• Placental abruption
• Placental insufficiency: This is a condition in which the placenta does not function properly, leading to an insufficient supply of oxygen and nutrients to the developing baby, potentially affecting amniotic fluid production.
• Twin-twin transfusion
• Placental thrombosis or infarction

Diagnosis

Clinical manifestation

The volume of amniotic fluid typically increases until 36 weeks and starts decreasing after 40 weeks in post-term gestations. For this reason, discrepancies between fundal height measurements and gestational age can be a clinical indication of amniotic fluid abnormality and should be evaluated by ultrasound. The symptoms of anhydramnios may not always be apparent, but some potential signs include:

• A decrease in the size of the baby's abdomen
• Decreased fetal movement
• Uterine contractions not associated with pain

Diagnosis

Diagnosis of oligohydramnios or anhydramnios is made by conducting a transabdominal ultrasound of the abdomen.

There are two methods that can be used to make the diagnosis: the amniotic fluid index (AFI) and the single deepest pocket (SDP) measuremen. An AFI of less than 5 cm or an SDP of less than 2 cm indicates oligohydramnios, and an AFI of 0 cm or an absent SDP indicates anhydramnios. In measuring the AFI, the sonographer measures the amniotic fluid in each of the four quadrants of the abdomen (right upper quadrant, left upper quadrant, right lower quadrant, left lower quadrant) and adds the values together. For reference, a normal AFI is 5–25 cm. An AFI <5 cm is considered oligohydramnios and an AFI >25 cm is considered polyhydramnios. Randomized control trials have shown that use of AFI can cause an increased number of false positive diagnosis of oligohydramnios and recommend using the measurement of a single deepest pocket (SDP) of amniotic fluid to diagnose oligohydramnios instead.

To calculate a single deepest pocket, the sonographer scans each of the four quadrants of the abdomen looking for the deepest pocket of amniotic fluid that does not include any fetal body parts or an umbilical cord. It is measured from the 12 o'clock position to the 6 o'clock position. For reference, a normal SDP is 2–8 cm. A SDP <2 cm is considered oligohydramnios and a SDP >8 cm is considered polyhydramnios. The use of a SDP for diagnosis of oligohydramnios is associated with less false positives and thus less unnecessary interventions without an increase in adverse perinatal outcomes.

In a multiple gestation pregnancy, measuring a single deepest pocket is the most accurate determination of adequate amniotic fluid levels.

Management

After initial diagnosis of oligohydramnios has been made, the next step is to perform a thorough history and physical exam, followed by diagnostic testing if indicated. Timely diagnosis and proper intervention for anhydramnios can significantly enhance the outlook for infants affected by this condition. The treatment depends on the underlying cause and may include:

• Amnioinfusion: Injection of amniotic fluid into the womb, can help to improve fetal lung development and reduce the risk of complications
• Fetal monitoring: Close monitoring of the fetus is crucial to assess its well-being and detect any potential complications
• Delivery: The timing of delivery may need to be adjusted depending on the severity of anhydramnios and the health of the fetus

Other point to note are:

• Retaking a maternal and family history and performing a physical exam can point to maternal conditions or medications that might be causing the oligohydramnios.
• Premature prelabor rupture of membranes or prelabor rupture of membranes is ruled out with a nitrizine test, evidence of ferning, or evidence pooling of liquid in the cervix.
• Sonographic evaluation of the fetus is done to identify fetal anomalies, aneuploidy, fetal growth restriction, or placental abnormalities. The National Institute of Health recommends detailed documentation of certain fetal organs that are most likely to be involved such as the kidneys, bladder, and the umbilical cord. If the lack of amniotic fluid prevents accurate visualization on ultraosund, MRI imaging can be considered. Genetic testing can be useful if fetal anomalies are documented on imaging.
• An elevated maternal serum alpha fetal protein (MSAFP) can indicate leaking amniotic fluid due to damage to fetal membranes or the placenta. This is associated with a poor prognosis.
• A maternal blood test or amniotic fluid test can be performed if suspicion of a TORCH infection is high.

Increasing amniotic fluid

There is no way to permanently increase the volume of amniotic fluid, but it can be temporarily increased to allow for a complete anatomy scan of the fetus on ultrasound.

One way to achieve this is through an amnioinfusion, which is the insertion of 200 mL of saline into the amniotic sac. One study showed an improvement in fetal structure visibility by 26% (51% to 77% before and after the infusion respectively). There is also some low quality data that may indicate a potential benefit of amnioinfusion is to facilitate external cephalic version. Amnioinfusion can be used during labor to prevent umbilical cord compression. There is uncertainty about the procedure's safety and efficacy, and it is recommended that it should only be performed in centers specializing in invasive fetal medicine and in the context of a multidisciplinary team.

One to two liters of oral hydration can temporarily increase amniotic fluid in dehydrated patients with isolated oligohydramnios.

Other investigational therapies may also be useful such as desmopressin, tissue sealants, or sildenafil citrate. These methods are less commonly used and are experimental.

In case of congenital lower urinary tract obstruction, fetal surgery seems to improve survival, according to a randomized yet small study.

Prenatal care

Patients who are preterm are managed in the outpatient setting with weekly or biweekly testing to monitor for accurate fetal growth and decrease chances of unexpected fetal death. This includes a weekly non-stress test (NST) and single deepest pocket (SDP) assessment which is also referred to as the modified BPP. Sonographic fetal growth exams may also be indicated.

Timing of delivery

Idiopathic, uncomplicated, and persistent oligohydramnios can be delivered at 36 0/7 weeks – 37 6/7 weeks of gestation or at diagnosis if diagnosis is later.

Complications

Complications may include cord compression, musculoskeletal abnormalities such as facial distortion and clubfoot, pulmonary hypoplasia and intrauterine growth restriction. Amnion nodosum is frequently also present (nodules on the fetal surface of the amnion).

The use of oligohydramnios as a predictor of gestational complications is controversial.

Potter syndrome is a condition caused by oligohydramnios. Affected fetuses develop pulmonary hypoplasia, limb deformities, and characteristic facies. Bilateral agenesis of the fetal kidneys is the most common cause due to the lack of fetal urine.

Prognosis

The prognosis of anhydramnios depends on the underlying cause and the severity of the condition. In general, the prognosis is poor for babies with anhydramnios caused by fetal renal abnormalities, with a high mortality rate. However, the prognosis is better for babies with anhydramnios caused by other factors, such as premature rupture of membranes (PPROM).

Factors that affect the prognosis of anhydramnios include:

• The underlying cause of the anhydramnios: Babies with anhydramnios caused by fetal renal abnormalities have a much poorer prognosis than babies with anhydramnios caused by other factors.
• The severity of the anhydramnios: Babies with severe anhydramnios have a poorer prognosis than babies with mild anhydramnios.
• The gestational age at diagnosis: Babies with anhydramnios diagnosed in the early stages of pregnancy have a poorer prognosis than babies with anhydramnios diagnosed in the later stages of pregnancy.
• The presence of other complications: Babies with anhydramnios who also have other complications, such as fetal growth restriction or skeletal deformities, have a poorer prognosis than babies with anhydramnios who do not have other complications.

With early diagnosis and appropriate treatment, many babies with anhydramnios can be born healthy. However, the prognosis for babies with anhydramnios caused by fetal renal abnormalities remains poor. These babies may require long-term medical care and may have developmental disabilities.

See also

• Fetal intervention
• Potter's sequence

References

1. ^ "Antepartum Fetal Surveillance". www.acog.org. Retrieved 2021-11-07.
2. ^ "UpToDate". www.uptodate.com. Retrieved 2021-11-07.
3. Grijseels, E. W. M.; van-Hornstra, PTM Echteld; Govaerts, L. C. P.; Cohen-Overbeek, T. E.; de Krijger, R. R.; Smit, B. J.; Cransberg, K. (2011-07-14). "Outcome of pregnancies complicated by oligohydramnios or anhydramnios of renal origin". Prenatal Diagnosis. 31 (11): 1039–1045. doi:10.1002/pd.2827. ISSN 0197-3851. PMID 21755519. S2CID 35572158.
4. ^ Keilman, Courtney; Shanks, Anthony L. (2021), "Oligohydramnios", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32965997, retrieved 2021-11-07
5. ^ "UpToDate". www.uptodate.com. Retrieved 2021-11-07.
6. Paternoster, Delia M.; Snijders, Deborah; Manganelli, Francesca; Torrisi, Angela; Bracciante, Roberto (2003). "Anhydramnios and maternal thrombocytopenia after prolonged use of nimesulide". European Journal of Obstetrics & Gynecology and Reproductive Biology. 108 (1): 97–98. doi:10.1016/s0301-2115(02)00343-3. ISSN 0301-2115. PMID 12694979.
7. Palermo, Mario S. F.; Espinosa, Ana; Trasmonte, Mónica (2021-11-19), "Disorders of Amniotic Fluid Volume: Oligoamnios and Polyhydramnios", Perinatology, Cham: Springer International Publishing, pp. 687–705, doi:10.1007/978-3-030-83434-0_39, ISBN 978-3-030-83433-3, retrieved 2023-11-21
8. Jelin, Angie C.; Sagaser, Katelynn G.; Forster, Katherine R.; Ibekwe, Tochi; Norton, Mary E.; Jelin, Eric B. (2020-02-19). "Etiology and management of early pregnancy renal anhydramnios: Is there a place for serial amnioinfusions?". Prenatal Diagnosis. 40 (5): 528–537. doi:10.1002/pd.5658. ISSN 0197-3851. PMC 7780162. PMID 32003482.
9. Atkinson, Meredith A.; Jelin, Eric B.; Baschat, Ahmet; Blumenfeld, Yair J.; Chmait, Ramen H.; O'Hare, Elizabeth; Moldenhauer, Julie S.; Zaretsky, Michael V.; Miller, Russell S.; Ruano, Rodrigo; Gonzalez, Juan M.; Johnson, Anthony; Mould, W. Andrew; Davis, Jonathan M.; Hanley, Daniel F. (2022). "Design and Protocol of the Renal Anhydramnios Fetal Therapy (RAFT) Trial". Clinical Therapeutics. 44 (8): 1161–1171. doi:10.1016/j.clinthera.2022.07.001. ISSN 0149-2918. PMC 9847373. PMID 35918190.
10. Riska, Anggun Hatika; Yusrawati, Yusrawati; Efrida, Efrida (2022-09-02). "Korelasi Asupan Vitamin C dan vitamin D dengan Kadar Timbal Ibu Hamil Preeklamsia". Indonesian Journal of Obstetrics & Gynecology Science. 5 (2): 284–292. doi:10.24198/obgynia/v5n2.430. ISSN 2615-496X.
11. Hromadnikova, Ilona; Kotlabova, Katerina; Hympanova, Lucie; Krofta, Ladislav (2016). "Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood". Thrombosis Research. 137: 126–140. doi:10.1016/j.thromres.2015.11.032. ISSN 0049-3848. PMID 26632513.
12. Vikraman, Seneesh Kumar; Chandra, Vipin; Balakrishnan, Bijoy; Batra, Meenu; Sethumadhavan, Sreeja; Patil, Swapneel Neelkanth; Nair, Sabila; Kannoly, Gopinathan (2017). "Impact of antepartum diagnostic amnioinfusion on targeted ultrasound imaging of pregnancies presenting with severe oligo- and anhydramnios: An analysis of 61 cases". European Journal of Obstetrics & Gynecology and Reproductive Biology. 212: 96–100. doi:10.1016/j.ejogrb.2017.03.026. ISSN 0301-2115. PMID 28349892.
13. Bader, Arnim A; Schlembach, Dietmar; Tamussino, Karl F; Pristauz, Gunda; Petru, Edgar (2007). "Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy". The Lancet Oncology. 8 (1): 79–81. doi:10.1016/s1470-2045(06)71014-2. ISSN 1470-2045.
14. Io, Shingo; Kondoh, Eiji; Chigusa, Yoshitsugu; Tani, Hirohiko; Hamanishi, Junzo; Konishi, Ikuo (2017-11-20). "An experience of second-trimester anhydramnios salvaged by single amnioinfusion". Journal of Medical Ultrasonics. 45 (3): 525–527. doi:10.1007/s10396-017-0842-1. ISSN 1346-4523. S2CID 22787864.
15. Visvalingam, G.; Purandare, N.; Cooley, S.; Roopnarinesingh, R.; Geary, M. (2011-12-20). "Perinatal outcome after ultrasound diagnosis of anhydramnios at term". Journal of Obstetrics and Gynaecology. 32 (1): 50–53. doi:10.3109/01443615.2011.618891. ISSN 0144-3615. PMID 22185537. S2CID 23539855.
16. Spiro, Judith Eva; Konrad, Martin; Rieger-Fackeldey, Esther; Masjosthusmann, Katja; Amler, Susanne; Klockenbusch, Walter; Schmitz, Ralf (2015-02-13). "Renal oligo- and anhydramnios: cause, course and outcome—a single-center study". Archives of Gynecology and Obstetrics. 292 (2): 327–336. doi:10.1007/s00404-015-3648-7. ISSN 0932-0067. PMID 25676656. S2CID 21433366.
17. Hansen, Wendy F.; Cooper, Christopher S.; Yankowitz, Jerome (2002). "Ureterocele Causing Anhydramnios Successfully Treated With Percutaneous Decompression". Obstetrics & Gynecology. 99 (5, Part 2): 953–956. doi:10.1097/00006250-200205001-00033. ISSN 0029-7844.
18. Gramellini, D.; Fieni, S.; Kaihura, C.; Piantelli, G.; Verrotti, C. (2003). "Antepartum amnioinfusion: a review". The Journal of Maternal-Fetal & Neonatal Medicine. 14 (5): 291–296. doi:10.1080/jmf.14.5.291.296. ISSN 1476-7058. PMID 14986801. S2CID 19890702.
19. Oligohydramnios Archived 2016-09-20 at the Wayback Machine at the National Institute for Health and Clinical Excellence. Based on the overview Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) Archived 2013-02-18 at the Wayback Machine in 2006
20. Hofmeyr, G. J.; Gülmezoglu, A. M. (2002). "Maternal hydration for increasing amniotic fluid volume in oligohydramnios and normal amniotic fluid volume". The Cochrane Database of Systematic Reviews (1): CD000134. doi:10.1002/14651858.CD000134. ISSN 1469-493X. PMC 7045461. PMID 11869566.
21. Morris, R. K.; Malin, G. L.; Quinlan-Jones, E.; Middleton, L. J.; Hemming, K.; Burke, D.; Daniels, J. P.; Khan, K. S.; Deeks, J.; Kilby, M. D. (2013). "Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): A randomised trial". The Lancet. 382 (9903): 1496–1506. doi:10.1016/S0140-6736(13)60992-7. PMC 3898962. PMID 23953766.
22. Adeniran AJ, Stanek J (2007). "Amnion nodosum revisited: clinicopathologic and placental correlations". Arch Pathol Lab Med. 131 (12): 1829–33. doi:10.5858/2007-131-1829-ANRCAP. PMID 18081444.
23. Johnson JM, Chauhan SP, Ennen CS, Niederhauser A, Magann EF (2007). "A comparison of 3 criteria of oligohydramnios in identifying peripartum complications: a secondary analysis". Am. J. Obstet. Gynecol. 197 (2): 207.e1–7, discussion 207.e7–8. doi:10.1016/j.ajog.2007.04.048. PMID 17689653.
24. Elsandabesee D, Majumdar S, Sinha S (2007). "Obstetricians' attitudes towards 'isolated' oligohydramnios at term". Journal of Obstetrics and Gynaecology. 27 (6): 574–6. doi:10.1080/01443610701469669. PMID 17896253. S2CID 39603642.

External links

• 00435 at CHORUS

• Pathology of pregnancy, childbirth and the puerperium